By targeting potential biomarkers associated with AIS etiology such as COMT and MTHFR, therapeutic modalities targeted specifically to these biomarkers could be further studied with the goal of decreasing the risk of progression in the adolescent years before skeletal maturity as this is when progression risk is the greatest18. Here, MTHFR is linked to androgen insensitivity syndrome.